
[2-(2-dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-thia-2- azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoate
1.狹心症:
通常成人1次30mg Diltiazem HCl,1日服用3次。症狀較重時,可增量至1次60mg,1日服用3次。
2.輕度至中度之本態性高血壓:
通常成人1次30~60mg Diltiazem HCl,1日服用3次。
又,依年齡、症狀適宜增減用量。
吸收、分佈、代謝:
口服本藥之生體可用率為40%。本藥大部分經由肝臟代謝,有2~4%以未改變汁形式經由尿排泄。本藥有70~80%會和血漿蛋白結合。口服本藥30~120mg後,30~60分鐘內可在血漿中測得,而在2~3小時內可得最高血中濃度。本藥口服單一或多次劑量其血中半衰期約為3.5小時。本藥之治療血中濃度範圍為50~200ng/ml。
Anesthetics
Depression of cardiac contractility, conductivity, and automaticity as well as vascular dilation associated with anesthetics may be potentiated.
Benzodiazepines (eg, midazolam, triazolam), carbamazepine, cyclosporine, digitalis, encainide, lovastatin
Plasma levels of these agents may be elevated by diltiazem, increasing the pharmacologic and toxic effects.
Beta-blockers
May have additive negative inotropic and chronotropic effects.
Cimetidine, ranitidine
Diltiazem levels may be increased.
Other antihypertensive agents
May have additive effects.
Rifampin
Coadministration lowered diltiazem plasma concentrations to undetectable levels.
2.孕婦及可能懷孕之婦女。
1.鈣離子拮抗劑突然中止使用時,有症狀惡化之報告,故欲停用本劑時應漸漸減少劑量,並仔細觀察。
2.本藥並不能阻止急性狹心症發作。
3.注意不要讓患者在沒有醫師指導下停藥。



